DiaMedica Therapeutics Announces Closing of 375 Million Private Placement

MINNEAPOLIS–(BUSINESS WIRE)– DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors. The Company sold approximately 11.0 million common shares a purchase price of $3.40…Read More